Diclofenac and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are Competitive Antagonists of the human P2X3 Receptor
L. Grohs, L. Cheng, S. Coenen, B. Haddad, A. Obrecht, I. Toklucu, L. Ernst, J. Koerner, G. Schmalzing, A. Lampert, J.-P. Machtens, R. Hausmann
Abstract
The P2X3 receptor (P2X3R), an ATP-gated non-selective cation channel of the P2X receptor family, is expressed in sensory neurons and involved in nociception. P2X3R inhibition was shown to reduce chronic and neuropathic pain. In a previous screening of 2000 approved drugs, natural products and bioactive substances, various non-steroidal anti-inflammatory drugs (NSAIDs) were found to inhibit P2X3R-mediated currents. To investigate whether the inhibition of P2X receptors contributes to the analgesic effect of NSAIDs, we characterized the potency and selectivity of various NSAIDs at P2X3R and other P2XR subtypes using two-electrode voltage clamp electrophysiology. We identified diclofenac as a hP2X3R and hP2X2/3R antagonist with micromolar potency (with IC50 values of 138.2 {micro}M and 76.7 {micro}M, respectively). A weaker inhibition of hP2X1R, hP2X4R and hP2X7R by diclofenac was determined. Flufenamic acid (FFA) proved to inhibit hP2X3R, rP2X3R and hP2X7R (IC50 values of 221{micro}M, 264.1{micro}M and [~] 900{micro}M, respectively), questioning its widespread use as a nonselective ion channel blocker, when P2XR-mediated currents are under study. Inhibition of the hP2X3R or hP2X2/3R by diclofenac could be overcome by prolonged ATP-application or increasing concentrations of the agonist ,{beta}-meATP, respectively, indicating competition of diclofenac and the agonists. Molecular dynamics simulation showed that diclofenac largely overlaps with ATP bound to the open state of the hP2X3R. Our results strongly support a competitive antagonism through which diclofenac, by interacting with residues of the ATP-binding site, left flipper, and dorsal fin domains inhibits gating of P2X3R by conformational fixation of the left flipper and dorsal fin domains. In summary, we demonstrate the inhibition of the human P2X3 receptor by various NSAIDs. Diclofenac proved to be the most effective antagonist with a strong inhibition of hP2X3R and hP2X2/3R and a weaker inhibition of hP2X1R, hP2X4R and hP2X7R. Considering their involvement in nociception, inhibition of hP2X3R and hP2X2/3R by micromolar concentrations of diclofenac may contribute to the analgesic effect as well as the side effect of taste disturbances of diclofenac and represent an additional mode of action besides the well-known high potency COX inhibition.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cryo-EM reveals the structural basis of subtype-specific, noncompetitive inhibition of the human P2X3 receptor
Zhixuan Zhao, Dong-Ping Wang, … Motoyuki Hattori·bioRxiv·Jan 3, 2026
- Structural insights into the orthosteric inhibition of P2X receptors by non-ATP-analog antagonists
D. Sheng, C. Yue, … M. Hattori·bioRxiv·Sep 15, 2023
- Equivalent excitability through different sodium channels and implications for the analgesic efficacy of selective drugs
Yu‐Feng Xie, Jane Yang, … Steven A. Prescott·eLifePeer-reviewed·Apr 30, 2024
- Diclofenac-eugenol modulation of Kv7 and TRPV1 ion channels
Adrián Rivera-Ruedas, Alejandro Rafael Medina-Vilchis, … Víctor De la Rosa·Canadian Journal of Physiology and PharmacologyPeer-reviewed·Jul 31, 2025
- Targeting the Schwann Cell EP2/cAMP Nanodomain to Block Pain but not Inflammation
Romina Nassini, Lorenzo Landini, … Pierangelo Geppetti·Nature CommunicationsPeer-reviewed·Sep 25, 2025
- Modulation of human dorsal root ganglion neuron excitability by Nav1.7 inhibition
Akie Fujita, Sooyeon Jo, … Bruce P. Bean·eLifePeer-reviewed·Oct 23, 2026